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Abstract
Objective—To examine the associations of cigarette smoking with rheumatoid arthritis (RA) in
African Americans and to determine to whether this association is impacted by HLA-DRB1 shared
epitope (SE).
Methods—Smoking status, cumulative smoking exposure, and SE status were measured in
African American patients with RA and in healthy controls. Associations of smoking with RA
were examined using age- and gender-adjusted logistic regression. Additive and multiplicative SE-
smoking interactions were examined.
Results—After adjusting for age and gender, ever (OR = 1.45; 95% CI 1.07 to 1.97) and current
smoking (OR = 1.56; 95% CI 1.07 to 2.26) were more common in African American RA cases (n
= 605) than in controls (n = 255). The association of smoking with RA was limited to those with a
cumulative exposure exceeding 10 pack-years, associations that were evident in both autoantibody
positive and negative disease. There was evidence of a significant additive interaction between SE
status and heavy smoking (≥ 10 pack-years) in RA risk (attributable proportion due to interaction
[AP] of 0.58, p = 0.007) with an AP of 0.47 (p = 0.006) between SE status and ever smoking.
There was no evidence of multiplicative interactions.
Conclusion—Among African Americans, cigarette smoking is associated not only with the risk
of autoantibody positive RA but also with the risk of autoantibody negative disease. RA risk
attributable to smoking is limited to African Americans with more than 10 pack-years of exposure
and is more pronounced among individuals positive for HLA-DRB1 SE.
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Since initial reports published more than twenty years ago (1), cigarette smoking has
repeatedly been shown to be associated with rheumatoid arthritis (RA) susceptibility (2–10),
a risk most pronounced among heavy smokers (2,11). Studies in populations of European
ancestry have shown that the relationship of smoking with RA risk appears to be impacted
by the presence of HLA-DRB1 shared epitope (SE) containing alleles (7,12,13), but the
mechanisms underpinning this interaction have yet to be fully defined. The associations of
cigarette smoking with disease risk in populations of European ancestry also appear to be
limited to those developing seropositive RA, which is characterized by the presence of either
rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP) antibody in the serum
(2,6).
Prior reports examining the association of cigarette smoking with RA risk have almost
exclusively involved populations of European ancestry. The lack of such studies among
African Americans represents an important gap in our knowledge. Although smoking is less
frequent in African Americans than in persons of European ancestry (14), smoking
incidence appears to be increasing in this population (15) and concomitant rates of smoking
cessation in African Americans are consistently lower compared to Caucasians (16). It is
unknown whether smoking contributes to RA risk in African Americans and whether this
risk is impacted by the presence of HLA-DRB1 SE, a genetic risk factor that is less prevalent
in African Americans with RA than in individuals of European ancestry with RA (17). To
address these knowledge gaps, we conducted a case-control study to examine the association
of cigarette smoking with RA among African Americans, to assess the impact of cumulative




RA cases and healthy controls were participants in the Consortium for the Longitudinal
Evaluation of African-Americans with Early Rheumatoid Arthritis (CLEAR) (18–20). All
cases satisfied the American College of Rheumatology (ACR) RA classification criteria (21)
and all study participants self-reported African American race. Additional information
regarding African American heritage (race/ethnicity of parents, grandparents) was not
collected. This study included cases and controls from CLEAR-I (RA cases had ≤ 2 years
disease duration from time of symptom onset) and CLEAR-II (cases with any disease
duration).
African American controls were enrolled based on age, gender, and geographic residence
and were recruited predominantly based on lists of telephone numbers from individuals
residing in the same mailing zip codes as those of RA cases. These lists were obtained from
Genesys / Marketing Systems Group (http://www.m-s-g.com/default.htm). Telephone
numbers were selected from census tracts with high percentages of African Americans near
the sites enrolling cases. Controls were selected within an age range of ± 10 years based on
the mean age of RA cases at each site at a female to male ratio of 3:1 based on the
anticipated gender distribution in cases. Potential controls were called by interviewers to
determine eligibility and interest and lists of suitable control subjects were then distributed
to the sites to arrange study visits.
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RA cases and controls were enrolled through one of five sites: the University of Alabama at
Birmingham (Birmingham, AL), Emory University (Atlanta, GA), Medical University of
South Carolina (Charleston, SC), the University of North Carolina (Chapel Hill, NC), and
Washington University (St. Louis, MO). The study was approved by the Institutional
Review Board (IRB) at each participating center and all study subjects provided informed
written consent prior to participation. Subjects missing data for either smoking status or
cumulative smoking exposure were excluded from the analysis (11 RA cases and 7 controls
excluded), leaving 605 RA cases and 255 healthy controls evaluable for this analysis.
Smoking status
Information regarding smoking status (current, former, never) was collected at the time of
enrollment, and among ever smokers, pack-years of smoking served as the measure of
cumulative exposure. Never smoking was defined as having smoked fewer than 100
cigarettes in the subject’s lifetime. Former smokers included individuals smoking ≥ 100
cigarettes over the subject’s lifetime but who quit smoking any time prior to study
enrollment. Based on recent reports examining the association of heavy smoking with RA
risk among women of European ancestry (11), ever smokers were further categorized based
on the magnitude of cumulative exposure (< 10 pack-years and ≥ 10 pack-years).
Information specific to ‘second-hand’ or other environmental smoking exposures were not
collected as part of this study.
Autoantibody measurement
Autoantibody measurements including anti-CCP antibody and RF, were performed as
previously reported using commercially available ELISA kits (18). Anti-CCP antibody (IgG,
Diastat, Axis-Shield Diagnostics Ltd., Dundee, Scotland, UK) was measured in arbitrary
units (U) per ml and was considered to be positive at a cut-off value ≥ 5 U/ml (18). RF
(IgM, INOVA Diagnostics Inc., San Diego, CA, USA) was measured in international units
(IU) per ml and was considered positive at concentrations ≥ 9.5 IU/ml (18).
HLA-DRB1 genotyping
High resolution HLA-DRB1 genotyping was performed as previously described, with a
previous report showing a higher frequency of SE-containing alleles in African American
cases compared to controls(22). HLA-DRB1 SE status was not available for 13 cases (2% of
all cases) and 5 controls (2%); these subjects were excluded from analyses that included SE
status.
Ancestral Informative Markers (AIMs)
To examine potential ancestral differences in cases and controls, DNA samples from a
subset of CLEAR RA cases (n = 561) and controls (n = 231) were genotyped using a custom
Illumina chip with 3,317 AIM markers in the laboratory of Dr. Peter Gregersen as part of the
International MHC and Autoimmunity Genetics Network (IMAGEN) (23). The percent
European ancestry for each participant was calculated based on the AIM genotypes using the
software package Structure Version 2.3.1 (24). Simulations were run assuming two founding
populations, 10,000 burnins, and 1,000 subsequent replicates to generate the estimates.
Statistical analysis
Subject characteristics (RA cases vs. controls) including the level of European ancestry were
compared using descriptive statistics, the Chi-square test for dichotomous variables, and the
Student’s t-test for continuous variables. Associations of smoking (current and former vs.
never) with case status were examined using unconditional logistic regression, adjusting for
age and gender given the differences in these characteristics between cases and controls. To
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account for effects of cumulative exposure, we examined the associations of heavy smoking
(≥ 10 pack-years) with RA risk referent to individuals reporting never smoking combined
with individuals reporting < 10 pack-years of smoking. In additional analyses, we examined
the aforementioned smoking variables with the risk of autoantibody positive and negative
disease, examining associations with anti-CCP antibody and RF positive disease in separate
models. Given the small proportion of healthy controls positive for anti-CCP antibody or
RF, all controls (n = 255) were included in analyses examining associations of smoking with
autoantibody positive and negative RA.
To explore the potential interactions between smoking and HLA-DRB1 SE, additional
models stratified by SE status (0 vs. 1 or 2 alleles) were examined. A potential ‘dose effect’
of SE was not examined given the low proportion of African American RA cases
homozygous for HLA-DRB1 SE. Analyses stratified by SE status and examining the risk of
autoantibody positive and negative RA were considered exploratory. For stratified analyses
with small ‘cell sizes’, we also examined the associations of smoking with disease risk using
Firth’s penalized likelihood approach, which is an alternative method of addressing issues of
small sample sizes and resulting bias in parameter estimates (25,26).
SE-smoking interactions were examined in two ways. First, we evaluated evidence of
departure from additivity using methods previously described by Rothman and colleagues
(27). This method has been used in other major epidemiological studies in RA examining
additive interactions of HLA-DRB1 SE and smoking (2,6,11,28). Using the methods detailed
by Andersson et al (29), we calculated the attributable proportion (AP) due to interaction as
the primary measure of additive interaction (AP = 0 corresponds to no interaction and an AP
= 1.0 corresponds to ‘complete’ additive interaction). Secondary measures of additive
interaction included the relative excess risk due to interaction (RERI), and the synergy index
(SI) (29). Confidence intervals (95% CIs) were calculated for the AP, RERI, and SI using
the method of Hosmer and Lemeshow (30). A p-value < 0.05 for AP was considered to
represent statistically significant additive interaction. Multiplicative interaction was then
assessed by modeling the SE-smoking product term in age- and gender-adjusted logistic
regression models. To optimize study power, interactions were limited to dichotomous
variables (SE-positive vs. SE-negative, ever vs. never smoking, and ≥ 10 pack-years vs.
never / < 10 pack-years) and to two-way interactions.
We calculated minimal detectable odds ratios (ORs) for the main effects of ever smoking
and heavy smoking with 80% power using a statistical threshold of α = 0.05 (one-sided),
assuming that 10% of the variability in multivariate analyses would be explained by
covariates. Based on the number of cases and controls available and the smoking exposures
observed, the study was powered to detect minimal detectable OR of 1.45 for ever smoking
with similar power for the associations of heavy smoking. Based on the assumption that the
presence of one risk factor in isolation (SE or smoking) would have an OR = 2.0, we had
78% power to detect a SI of 2.55 for the interaction between SE and ever smoking and 60%
power to detect a SI of 2.88 for the interaction between SE and heavy smoking. All analyses
were conducted using SAS v9.2 (SAS Institute Inc., Cary, NC).
Results
There were 605 RA cases and 255 healthy controls included in the analysis. Characteristics
of cases and controls are shown in Table 1. There were more women among RA cases than
among controls (84% vs. 76%, p = 0.004). RA cases were also slightly older than controls
(mean 54 vs. 52 years, p = 0.048) and were much more likely to have at least one HLA-
DRB1 SE containing allele (40% vs. 23%, p = 0.0001). Only 5% of African American RA
cases were homozygous for HLA-DRB1 SE. Among RA cases, the mean (± SD) disease
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duration was 6.3 ± 8.7 years (1.0 ± 0.6 years in CLEAR-I and 11.2 ± 9.9 years in CLEAR-
II) and most were positive for anti-CCP antibody (67%) or RF (76%). Mean (± SD) levels of
European admixture based on AIM genotyping did not differ between RA cases (0.14 ±
0.13) and controls (0.13 ± 0.11) (p = 0.59).
Smoking status and the frequency of heavy smoking (defined as ≥ 10 pack-years) among
RA cases and controls are shown in Table 1. Compared to healthy controls, RA cases were
slightly more likely to report former or current smoking and less likely to be never smokers
(p = 0.055). Among those reporting a history of ever smoking, heavy smoking was much
more common in RA cases (54% of ever smokers) than in controls (35% of ever smokers).
After adjusting for age and sex, RA cases were much more likely than controls to report
current smoking vs. never smoking (OR = 1.56; 95% CI 1.07 to 2.26) with a non-significant
trend towards higher rates of former smoking in cases (Table 2). As anticipated, the
association of ever smoking (OR = 1.45; 95% CI 1.07 to 1.97) with overall RA, referent to
never smoking, was intermediate to associations of current and former smoking.
Associations of smoking status with RF/anti-CCP antibody positive and negative RA are
shown in Table 2. The association of smoking with RA was greatest among heavy smokers
(vs. never smokers, OR = 2.37; 95% CI 1.56 to 3.60), an association that was significant for
both autoantibody positive and negative disease (Table 2), whether based on anti-CCP
antibody or RF status. In contrast, there were no associations of lower cumulative smoking
exposure (< 10 pack-years) with RA (Table 2).
Because analyses revealed that lower cumulative smoking exposures (< 10 pack-years) were
not associated with an increased risk of RA relative to never smoking, never smokers and
ever smokers with < 10 pack-years were combined in the subsequent analyses accounting
for cumulative smoking exposure. Compared to never smokers and those smoking < 10
pack-years combined, heavy smoking was significantly associated with the development of
both anti-CCP antibody positive (OR = 2.35; 95% CI 1.55 to 3.58) and anti-CCP antibody
negative RA (OR = 2.16; 95% CI 1.33 to 3.50), results that were similar to those
corresponding to RF positive and RF negative RA (Table 2). Age- and sex-adjusted
associations of heavy smoking with overall RA were examined separately and found to be
significant in both CLEAR-I (OR = 2.15; 95% CI 1.23 to 3.75) and CLEAR-II (OR = 2.48;
95% CI 1.39 to 4.42) (data not shown).
Age- and sex-adjusted associations of heavy smoking with RA, stratified by HLA-DRB1 SE
status, are shown in Figure 1. Based on the lower frequency of SE positivity among cases
and controls combined (35% of total participants SE positive), coupled with the small
number of controls with heavy smoking exposure (n = 39), confidence intervals were
universally wider for analyses limited to SE positive individuals compared to analyses in SE
negative individuals. Among African Americans with 1 or 2 SE alleles, heavy smoking was
associated with a more than 4-fold increased risk of RA (OR = 4.44; 95% CI 1.58 to 12.51).
Among SE negative African Americans, the association of heavy smoking was less striking
although it remained statistically significant (OR = 2.22; 95% CI 1.43 to 3.45). Associations
of heavy smoking with anti-CCP antibody positive and negative RA stratified by SE status
were similar to estimates observed for overall disease risk (Figure 1) as were results based
on RF positive and negative disease (data not shown). Results of these stratified analyses
were not changed after application of Firth’s penalized likelihood approach (25,26) to
account for small cell sizes (data not shown).
There was evidence of significant additive interaction of HLA-DRB1 SE status with heavy
smoking in overall RA disease (AP = 0.58; 95% CI 0.16 to 0.99, p = 0.007), an interaction
that was less striking but still significant with ever smoking (AP = 0.47; 95% CI 0.14 to
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0.80, p = 0.006) (Table 3). Corresponding measures of SI and RERI are shown in Table 3.
There was no evidence of multiplicative interaction between HLA-DRB1 SE and heavy
smoking (p = 0.38) or ever smoking (p = 0.17) in overall disease risk. APs corresponding to
HLA-DRB1-smoking interactions for anti-CCP antibody positive and anti-CCP antibody
negative RA are shown in Table 3, with similar values for measures of interaction
corresponding to RF positive and RF negative RA (data not shown). Additive interactions
between HLA-DRB1 SE and smoking were stronger for seropositive RA when compared to
seronegative RA. Results of these analyses were not changed when the amount of European
admixture based on AIM genotyping was included as a covariate in the models (data not
shown).
Discussion
To our knowledge, this is the first study to show an association of cigarette smoking with
RA in African Americans. We found that this association is most striking in heavy smokers
and those with HLA-DRB1 SE containing alleles. Among African Americans with a
cumulative smoking history exceeding 10 pack-years, the risk of RA is increased by more
than two-fold, and this risk is increased to more than four-fold in the presence of SE alleles.
In contrast, the risk of RA among ever smokers with a cumulative exposure of less than 10
pack-years appears to be negligible. Assuming that the smoking behaviors reported by
controls in this study (where 15% reported a smoking history of more than 10 pack-years)
reflect those of African Americans nationally, the attributable risk of RA due to heavy
smoking exposure in this population may be as high as 16%. Said in another way, our results
suggest that approximately 1 in 6 new cases of RA occurring in African Americans could be
prevented through smoking cessation or by limiting cumulative smoking exposure in this
population to less than 10 pack-years. In light of reports suggesting that smoking is on the
rise among African Americans (15), our results suggest that RA incidence and disease
burden may increase in this population over the next decades.
It is worth noting that some uncertainty remains regarding the optimal method to model
gene-environment interactions (31). In contrast to prior studies that have examined smoking-
SE interactions in RA risk using only additive interaction (2,6), we have examined measures
of both additive and multiplicative interaction. Multiplicative interaction refers to the
inclusion of a product term in regression analyses to generate an ‘optimal fit’ of the data in
the statistical model. It is important to note that the absence of multiplicative interaction
does not exclude the existence of important biologic or additive interactions, which in the
case of this study show that at least one ‘pathway’ to RA development in African Americans
requires the presence of two risk factors (i.e. heavy smoking and HLA-DRB1 SE).
The results presented here are similar to a recent report from the Nurses’ Health Study
(NHS), a nested case-control study of more than 100,000 women of European ancestry in
the U.S. including 680 women with incident RA (11). In the NHS study (11), investigators
found evidence of significant additive interaction between HLA-DRB1 and heavy smoking
(> 10 pack-years) in overall RA risk with an AP of 0.39 (95% CI 0.08 to 0.69, p = 0.01).
Although the NHS study did not yield evidence of multiplicative interaction in overall
disease risk (p = 0.14), there was evidence of a significant multiplicative interaction between
HLA-DRB1 SE and heavy smoking in the development of seropositive RA (a phenotype
based on RF status in some patients and anti-CCP antibody status in others) (11). The
absence of multiplicative interaction in our study of African Americans may relate to the
smaller number of study participants and limited power relative to the larger NHS study.
NHS investigators also found no evidence of additive interaction between HLA-DRB1 SE
and ever smoking status in disease risk (AP = 0.23; 95% CI −0.14 to 0.61, p = 0.23).
Evidence of additive interaction in CLEAR between SE and ever smoking was similarly
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attenuated compared to interaction between SE and heavy smoking, although still
statistically significant in CLEAR. Results from the NHS suggest that accounting for
cumulative exposure is essential in assessing the role of cigarette smoking and gene-
smoking interactions in RA. In light of our results, these conclusions can now be extended to
African Americans. Failure to account for smoking “dose” could explain the lack of
substantial SE-smoking interaction found in other North American cohorts (28).
Biologic interactions between HLA-DRB1 SE alleles and smoking in RA risk have been
shown in several epidemiological investigations, although ours is the first study to
exclusively involve African Americans. Taken together, these studies suggest that smoking
may trigger initial inflammatory events in RA that are HLA-DRB1 dependent. Previous
studies, which involved populations of European ancestry, have shown that SE-smoking
interactions are most evident in the development of anti-CCP antibody positive disease.
These results have been interpreted to mean that smoking either upregulates citrullination or
enhances the immunogenicity of citrullinated peptides in the context of select HLA alleles.
However, our study of African Americans showed that the associations of heavy smoking
with RA are similar for autoantibody positive and negative disease, although risk estimates
were consistently higher for seropositive RA. This finding is in direct contrast to results
from reports involving populations of European ancestry (2,11) and one that will require
replication in separate study populations. These results are consistent with a prior case-only
analysis done in a subset of CLEAR-I patients showing no association of smoking with anti-
CCP antibody positivity (32). In the present study of African Americans, heavy smoking
was associated with a significant and more than two-fold increased risk for both anti-CCP
antibody negative RA and RF negative RA. By contrast, in a large national case-control
study from Sweden, Klareskog and colleagues found no associations of smoking with the
risk of anti-CCP antibody negative RA, regardless of HLA DRB1 SE status (2). Reasons for
this apparent discrepancy are unknown, but it is possible that there are other genetic and/or
environmental factors that could mediate the effect of smoking in autoantibody negative RA
and the prevalence of these as of yet undefined factors could vary markedly in prevalence
based on race/ethnicity. In addition to differences in the study populations and accounting
for cumulative exposures, variations in study design, ascertainment of smoking status, and
different methods of analysis could also serve to explain differences across published
reports.
Limitations to this study are those inherent to its case-control design. These include possible
recall bias and the possibility of a “healthy responder” bias among controls. This latter
concern is mitigated by the recruitment and enrollment of healthy controls residing in the
same census tracts as RA cases, individuals similar to cases in regards to sociodemographic
characteristics and other “unmeasured confounders”. Similarities between cases and controls
were further borne out at the genetic level, with examinations of AIMS showing very similar
levels of European admixture in both groups.
The case-control design also prohibits conclusions regarding the ‘direction’ of the
associations examined, although for all RA cases included in this study initial smoking
exposure preceded disease onset, in most cases by many years. We also found no major
differences in risk estimates corresponding to heavy smoking in analyses limited to CLEAR-
I (RA cases with disease duration < 2 years) and analyses limited to CLEAR-II (RA cases
with any disease duration), suggesting that recall bias and protopathic bias (disease onset
leading to exposure) are less likely issues. If a protopathic bias had been operative in these
findings, we would have expected to have observed much stronger associations of heavy
smoking with RA in CLEAR-II, a cohort that included RA patients with established disease
and a much longer time interval between disease onset and study enrollment. Despite these
potential limitations, this effort represents the largest study to date examining the impact of
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smoking and gene-smoking interactions in RA in a well characterized African American
population, a group that has been vastly understudied in RA epidemiology.
In summary, cigarette smoking is significantly associated with RA in African Americans, an
association that is most pronounced with a cumulative smoking history exceeding 10 pack-
years. Similar to reports involving populations of European ancestry, the risk attributed to
smoking is highest in African Americans positive for HLA-DRB1 SE alleles with evidence
of a significant biologic interaction between SE and heavy smoking in RA risk.
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Age- and gender-adjusted associations of heavy smoking (≥ 10 pack-years vs. never or < 10
pack-years) with the risk of overall rheumatoid arthritis (RA), anti-CCP antibody positive
RA, and anti-CCP antibody negative RA in African Americans; analyses stratified by HLA-
DRB1 shared epitope (SE) status; Odds ratios (ORs) and 95% confidence intervals (CIs) are
shown; SE status missing for 13 (2%) of RA cases and 5 (2%) healthy controls.
Mikuls et al. Page 11

























Mikuls et al. Page 12
Table 1




(n = 255) P-value
Female sex 84 76 0.004
Age, years 54 (13) 52 (13) 0.048
Disease duration at baseline visit, years † 6.3 (9) ---- ----
Shared epitope positive (1 or 2 copies) 40 23 0.0001
Anti-CCP antibody positive* 67 4 < 0.0001
RF positive* 76 16 < 0.0001
Smoking status
    Never 48 56
    Former 25 22
    Current 27 23 0.055
Cumulative smoking exposure
    Never or < 10 pk-yrs 72 85
    Ever, ≥ 10 pk-yrs 28 15 < 0.0001
*
CCP = cyclic citrullinated peptide; RF = rheumatoid factor; HLA-DRB1 shared epitope (SE) data were not available for 13 (2%) of RA cases and
5 (2%) healthy controls; p-values calculated using Chi-square test or Student’s t-test.
†
Bimodal disease duration: for CLEAR-I mean (± SD) = 1.0 (0.6) years; for CLEAR-II mean 11.2 (9.9)
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Table 3
Measures interaction between HLA-DRB1 shared epitope (SE) containing alleles (1 or 2 copies vs. none) and
smoking in rheumatoid arthritis risk in African Americans*
All RA
Measures of Additive Interaction Ever smoking /SE ≥ 10 pack-years /SE
    Attributable proportion† (AP) (95% CI) 0.47 (0.14 to 0.80) 0.58 (0.16 to 0.99)
    P-value for interaction Padd = 0.006 Padd = 0.007
    Relative excess risk due to interaction (95% CI) 2.04 (−0.36 to 4.43) 4.86 (−3.08 to 12.80)
    Synergy Index (95% CI) 2.55 (0.99 to 6.60) 2.88 (0.92 to 9.04)
Measures of Multiplicative Interaction
    P-value of product term Pmult = 0.17 Pmult = 0.38
Anti-CCP Antibody Positive RA
Measures of Additive Interaction
    Attributable proportion† (AP) (95% CI) 0.53 (0.22 to 0.83) 0.63 (0.25 to 1.00)
    P-value for interaction Padd = 0.001 Padd = 0.001
    Relative excess risk due to interaction (95% CI) 3.16 (−0.22 to 6.54) 7.16 (−3.76 to 18.08)
    Synergy Index (95% CI) 2.70 (1.13 to 6.45) 3.17 (1.04 to 9.62)
Measures of Multiplicative Interaction
    P-value of product term Pmult = 0.13 Pmult = 0.36
Anti-CCP Antibody Negative RA
Measures of Additive Interaction
    Attributable proportion (AP)† (95% CI) 0.04 (−0.77 to 0.86) 0.24 (−0.69 to 1.17)
    P-value for interaction Padd = 0.92 Padd = 0.61
    Relative excess risk due to interaction (95% CI) 0.08 (−1.39 to 1.54) 0.81 (−3.17 to 4.80)
    Synergy Index (95% CI) 1.11 (0.15 to 8.38) 1.52 (0.26 to 9.04)
Measures of Multiplicative Interaction
    P-value of product term Pmult = 0.96 Pmult = 0.87
*
Additive interaction examined by assessing for evidence of departure from additivity in age- and sex-adjusted models; Multiplicative interaction
examined by modeling SE-smoking product term. Smoking examined as ever vs. never smoking and heavy smoking (≥ 10 pack-years) vs. other
(never or < 10 pack-years).
†
AP = 0 corresponds to no interaction and an AP = 1.0 corresponds to ‘complete’ additive interaction
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